고객지원자주 묻는 질문과 답을 확인하세요
전체
QWhy should newborns consider genomic newborn screening like 3B-NEO?
- Most rare genetic disorders appear healthy at birth externally, yet internally, irreversible damage has already begun — a diagnostic latency period. By using genomic analysis to screen for hundreds of Actionable (medically treatable) conditions that conventional biochemical screening (MS/MS) cannot detect, 3B-NEO secures the therapeutic window before symptoms appear, enabling timely intervention.
- This goes beyond the early detection of disease, as timely interventions—such as dietary management, medication, or gene therapy—can prevent physical and intellectual disabilities and fundamentally improve the patient’s lifelong prognosis.